SRPT - Sarepta Therapeutics, Inc.
IEX Last Trade
121.425
-0.665 -0.548%
Share volume: 11,390
Last Updated: Fri 27 Dec 2024 08:30:08 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$122.09
-0.67
-0.54%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-02 | 2022-11-02 | 2023-02-28 | 2023-05-02 | 2023-08-02 | 2023-11-01 | 2024-02-28 | 2024-05-01 | |
| Assets | |||||||||
| Total Assets | 2.997 B | 3.156 B | 3.128 B | 3.060 B | 3.126 B | 3.110 B | 3.265 B | 3.224 B | |
| Current Assets | 2.469 B | 2.626 B | 2.558 B | 2.488 B | 2.473 B | 2.451 B | 2.579 B | 2.465 B | |
| Inventories | 208.095 M | 221.192 M | 203.968 M | 202.675 M | 226.876 M | 244.011 M | 322.859 M | 373.530 M | |
| Other Current Assets | 102.911 M | 108.803 M | 104.822 M | 115.529 M | 117.865 M | 119.033 M | 177.164 M | 288.485 M | |
| Short Term Investments | 102.911 M | 108.803 M | 104.822 M | 115.529 M | 117.865 M | 119.033 M | 177.164 M | 288.485 M | |
| Total Receivables | 230.275 M | 223.450 M | 259.697 M | 288.076 M | 267.158 M | 354.263 M | 403.058 M | 412.107 M | |
| Current Cash | 1.928 B | 2.072 B | 1.989 B | 1.882 B | 1.861 B | 1.734 B | 1.676 B | 1.391 B | |
| Total Non-current Assets | 527.553 M | 530.220 M | 570.505 M | 571.409 M | 653.276 M | 658.858 M | 685.245 M | 759.520 M | |
| Property Plant Equipment | 183.292 M | 181.005 M | 180.037 M | 182.862 M | 188.874 M | 212.367 M | 227.154 M | 249.302 M | |
| Other Assets | 232.467 M | 240.856 M | 267.591 M | 269.308 M | 261.632 M | 266.887 M | 276.413 M | 331.983 M | |
| Intangible Assets | 13.062 M | 13.057 M | 7.578 M | 7.199 M | 18.018 M | 19.501 M | 29.620 M | 28.930 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 2.997 B | 3.156 B | 3.128 B | 3.060 B | 3.126 B | 3.110 B | 3.265 B | 3.224 B | |
| Total liabilities | 2.270 B | 2.725 B | 2.743 B | 2.347 B | 2.384 B | 2.345 B | 2.405 B | 2.263 B | |
| Total current liabilities | 545.566 M | 602.916 M | 619.604 M | 536.884 M | 498.654 M | 450.743 M | 653.659 M | 608.709 M | |
| Accounts Payable | 56.207 M | 118.461 M | 95.875 M | 106.710 M | 109.796 M | 87.948 M | 164.918 M | 91.536 M | |
| Other liabilities | 584.589 M | 544.394 M | 521.942 M | 521.938 M | 521.138 M | 523.100 M | 478.100 M | 380.722 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 105.483 M | 105.586 M | |
| Long term debt | 1.101 B | 1.543 B | 1.544 B | 1.234 B | 1.236 B | 1.237 B | 1.133 B | 1.134 B | |
| Other liabilities | 584.589 M | 544.394 M | 521.942 M | 521.938 M | 521.138 M | 523.100 M | 478.100 M | 380.722 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 726.457 M | 430.840 M | 384.950 M | 712.749 M | 741.411 M | 764.357 M | 859.337 M | 961.192 M | |
| Common stock | 87.511 M | 87.628 M | 87.844 M | 88.186 M | 88.743 M | 88.889 M | 103.774 M | 93.991 M | |
| Retained earnings | -3.543 B | -3.801 B | -3.910 B | -4.427 B | -4.451 B | -4.492 B | -4.446 B | -4.410 B |